12/10
12:56 pm
nrix
Rating for NRIX
Low
Report
Rating for NRIX
12/10
08:58 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) is now covered by analysts at BTIG Research. They set a "buy" rating and a $35.00 price target on the stock.
Low
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) is now covered by analysts at BTIG Research. They set a "buy" rating and a $35.00 price target on the stock.
12/10
08:01 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
Medium
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
12/10
07:22 am
nrix
Nurix Therapeutics initiated with a Buy at BTIG
Low
Report
Nurix Therapeutics initiated with a Buy at BTIG
12/10
06:01 am
nrix
Rating for NRIX
Low
Report
Rating for NRIX
12/10
06:01 am
nrix
Rating for NRIX
Low
Report
Rating for NRIX
12/6
08:06 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $35.00 price target on the stock.
Medium
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $35.00 price target on the stock.
12/6
06:12 am
nrix
Rating for NRIX
Medium
Report
Rating for NRIX
12/6
06:12 am
nrix
Rating for NRIX
Medium
Report
Rating for NRIX
12/5
04:12 pm
nrix
Nurix Therapeutics initiated with an Outperform at BMO Capital
Medium
Report
Nurix Therapeutics initiated with an Outperform at BMO Capital
12/5
04:12 pm
nrix
Nurix Therapeutics initiated with an Outperform at BMO Capital
Medium
Report
Nurix Therapeutics initiated with an Outperform at BMO Capital
11/6
08:07 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
Medium
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
11/6
06:07 am
nrix
Rating for NRIX
Medium
Report
Rating for NRIX
11/6
06:07 am
nrix
Rating for NRIX
Medium
Report
Rating for NRIX
10/24
07:44 am
nrix
Rating for NRIX
Low
Report
Rating for NRIX
10/24
07:16 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $35.00 price target on the stock.
Low
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $35.00 price target on the stock.
10/21
08:07 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
Low
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
10/21
07:13 am
nrix
Rating for NRIX
Low
Report
Rating for NRIX
10/21
07:13 am
nrix
Rating for NRIX
Low
Report
Rating for NRIX
10/14
09:41 am
nrix
Rating for NRIX
Medium
Report
Rating for NRIX
10/14
09:41 am
nrix
Rating for NRIX
Medium
Report
Rating for NRIX
10/14
09:09 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $31.00 price target on the stock.
Medium
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $31.00 price target on the stock.
10/14
09:09 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $31.00 price target on the stock.
Medium
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $31.00 price target on the stock.
10/14
09:00 am
nrix
Rating for NRIX
Medium
Report
Rating for NRIX
10/14
08:41 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
Medium
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.